CN100493608C - 含生物活性成份的气雾剂制备方法 - Google Patents
含生物活性成份的气雾剂制备方法 Download PDFInfo
- Publication number
- CN100493608C CN100493608C CNB200410084323XA CN200410084323A CN100493608C CN 100493608 C CN100493608 C CN 100493608C CN B200410084323X A CNB200410084323X A CN B200410084323XA CN 200410084323 A CN200410084323 A CN 200410084323A CN 100493608 C CN100493608 C CN 100493608C
- Authority
- CN
- China
- Prior art keywords
- polyoxyethylene
- laurate
- agent
- biological activity
- aerosol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 15
- 230000004071 biological effect Effects 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- MSSNHSVIGIHOJA-UHFFFAOYSA-N pentafluoropropane Chemical compound FC(F)CC(F)(F)F MSSNHSVIGIHOJA-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 239000003380 propellant Substances 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- -1 bronchodilator Substances 0.000 claims description 34
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 18
- 229940070765 laurate Drugs 0.000 claims description 18
- 239000002270 dispersing agent Substances 0.000 claims description 10
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 9
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 6
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 230000002421 anti-septic effect Effects 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 239000000375 suspending agent Substances 0.000 claims description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
- 239000005642 Oleic acid Substances 0.000 claims description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 4
- 229960003511 macrogol Drugs 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 claims description 3
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 3
- PRXRUNOAOLTIEF-WUOFIQDXSA-N sorbitan trioleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C\CCCCCCCC)C1OCC(O)C1OC(=O)CCCCCCC\C=C\CCCCCCCC PRXRUNOAOLTIEF-WUOFIQDXSA-N 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- HVUMOYIDDBPOLL-UHFFFAOYSA-N 2-(3,4-Dihydroxyoxolan-2-yl)-2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)C1OCC(O)C1O HVUMOYIDDBPOLL-UHFFFAOYSA-N 0.000 claims description 2
- IJCWFDPJFXGQBN-UHFFFAOYSA-N 2-[4-Hydroxy-3-(octadecanoyloxy)oxolan-2-yl]-2-(octadecanoyloxy)ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)C1OCC(O)C1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-UHFFFAOYSA-N 0.000 claims description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
- 229920006197 POE laurate Chemical class 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- 229920002642 Polysorbate 65 Polymers 0.000 claims description 2
- 229920002651 Polysorbate 85 Polymers 0.000 claims description 2
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 2
- 229960002747 betacarotene Drugs 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000004044 bronchoconstricting agent Substances 0.000 claims description 2
- 230000003435 bronchoconstrictive effect Effects 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims description 2
- 229940125692 cardiovascular agent Drugs 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 229940092456 curosurf Drugs 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 claims description 2
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 229940099511 polysorbate 65 Drugs 0.000 claims description 2
- 229940113171 polysorbate 85 Drugs 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- 235000013547 stew Nutrition 0.000 claims description 2
- 239000000814 tuberculostatic agent Substances 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
- 239000011343 solid material Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 2
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- 238000011049 filling Methods 0.000 abstract description 3
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 238000005429 filling process Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 229950008204 levosalbutamol Drugs 0.000 description 5
- 239000001117 sulphuric acid Substances 0.000 description 5
- 235000011149 sulphuric acid Nutrition 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 3
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 2
- 229960001361 ipratropium bromide Drugs 0.000 description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- OSNIIMCBVLBNGS-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one Chemical compound CN(C)C(C)C(=O)C1=CC=C2OCOC2=C1 OSNIIMCBVLBNGS-UHFFFAOYSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明属于药物制剂技术领域。本发明公开了一种含生物活性成份的气雾剂制备方法。本发明的制备中采用两步法罐装,应用五氟丙烷作为分散剂,在液化温度下,可以将加入赋形剂的主药分散成大体积,使主药分散均匀;并且使冲填时压力可调,有助于二次充填抛射剂,达到罐装充填的准确度。并且使成品罐内压力稳定,不爆瓶。本发明方法简便易行,宜于规模型工业化生产。
Description
技术领域
本发明属于药物制剂技术领域。具体涉及一种含生物活性成份的气雾剂制备方法。
背景技术
在药物制剂中,气雾剂常用于治疗有关呼吸系统疾病,通过口腔、鼻腔等给药方式进行吸入或喷雾递送,达到有效的治疗。在药用气雾剂的制备中,一般用氟化物来替换分散剂,常用的如p134a(1,1,1,2-四氟乙烷)和p227ea(1,1,1,2,3,3,3-七氟丙烷),但此两种氟化物对设备要求高,罐装充填时精确度难以保证,灌装蒸汽压不可调。CN1455663A专利中公开了一些可替换含氟抛射剂的氟化物,但是并没有提供五氟丙烷的应用。本发明人研究结果认为五氟丙烷用作气雾剂的分散剂(共溶剂),表现了极好的性能。
发明内容
本发明所要解决的技术问题在于选择五氟丙烷作为分散剂,设计一种药用气雾剂的制备方法。
本发明提供了一种含生物活性成份的气雾剂的制备方法。
本发明的制备方法是基于这样的原理,即本发明采用两步法罐装,因为五氟丙烷的液化温度为19度,而HFC-134a的液化温度为-26.1度,HFC-227ea的液化温度为-16.5度。所以在两步法罐装中,本发明选择先用五氟丙烷做分散剂,使其在液化温度下,将加入辅料及赋形剂等的主药分散成大体积,从而有助于二次充填抛射剂;由于五氟丙烷的蒸汽压1.12bar/20度,HFC-134a的蒸汽压为5.72bar/20度,HFC-227ea的蒸汽压为3.9bar/20度。所以在两步灌装法中,本发明选择先用五氟丙烷做分散剂,使其灌装过程中,蒸汽压可调,并且防止成品因罐内蒸汽压过高而爆瓶。
本发明的制备方法包括下列步骤:
①本发明气雾剂的活性成份与药用辅料按下列重量百分比组成:
活性成份 0.01%—1%
分散剂 5-50%
推进剂 50-90%
稳定剂 0-16%
表面活性剂 0.001-0.5%
助悬剂 0-5%
比重调节剂 0-0.5%
矫味剂 0-0.5%
抗氧剂 0-1.5%
防腐剂 0-0.5%
②将固体原辅料经真空干燥或温度小于80℃的条件下加热干燥数小时,置于干燥器皿内冷却至室温备用;
③使用经干燥至恒重的无水硫酸钠的重量大于液体辅料重量的20%,加入液体辅料中脱水不少于24小时;
④将固体原辅料采用气流粉碎法粉碎,并使用粒度分析仪检查粉碎后的固体原辅料粒度(小于10μm,大多数小于5μm),满足粒度要求合格的原辅料置于干燥器皿内密封保存备用;
⑤将处方量的原辅料及分散剂共同置于密封的配制罐内,高速匀质后,检验中间体的质量及含量,按所设计的处方,将合格的中间体灌入耐压容器中,加盖阀门并密封,充入处方量的抛射剂即可。
用于本发明制剂的适宜药物包括能通过吸入途径来进行给药的所有药物,例如:甾族化合物,肽,低核苷酸,小的有机分子等。特别是能通过pMDI(计量吸入器)进行给药的这些药物。该类药物不限制仅为那些用于治疗呼吸系统疾病的药物。包括那些适于通过经鼻进行递送和喷雾递送的药物。
生物活性剂可以选自任何治疗剂或诊断剂,选自抗变态反应药,支气管扩张药,支气管收缩药,肺部的肺表面活性剂,止痛剂,抗生素,白三烯抑制剂或拮抗剂,抗胆碱药,肥大细胞抑制剂,抗组胺药,抗肿瘤药,麻醉剂,抗结核药,显影剂,心血管药,酶,甾族化合物,基因物质,病毒媒介物,反义物质,蛋白质或肽的一种或任意两种的组合物。
本发明方法中的分散剂选自HFC-245fa(五氟丙烷);推进剂选择1,1,1,2-四氟乙烷或1,1,1,2,3,3,3-七氟丙烷或它们的混合组成。
表面活性剂选自:
脱水山梨醇脂肪酸酯类,如:司盘20(span20),司盘60(span60),司盘65(span65),司盘80(span80),司盘85(span85)等;
聚氧乙烯脱水山梨醇脂肪酸酯类,如:吐温20(tween20),吐温40(tween40),吐温60(tween60),吐温65(tween65),吐温80(tween80)或吐温85(tween85)等;
聚氧乙烯脂肪酸酯类,如:卖泽45(Myij45),卖泽52(Myij52),卖泽53(Myij53),卖泽59(Myij59)等;
聚氧乙烯月桂酸酯类,如:
Polyoxyethylene(4)Laurate(聚氧乙烯(4)月桂酸酯)
Polyoxyethylene(8)Laurate(聚氧乙烯(8)月桂酸酯)
Polyoxyethylene(12)Laurate(聚氧乙烯(12)月桂酸酯)
Polyoxyethylene(24)Laurate(聚氧乙烯(24)月桂酸酯)
Polyoxyethylene(40)Laurate(聚氧乙烯(40)月桂酸酯)
Polyoxyethylene(100)Laurate(聚氧乙烯(100)月桂酸酯)
磷脂类:如大豆磷脂、卵磷脂;
油酸;甘露醇
稳定剂选自:乙醇、丙醇、甘油、异丙醇、乙酸乙酯、聚乙二醇、丙二醇、二甲醚或其中一种或多种的混合物
聚乙二醇类,如:聚乙二醇200(PEG200),聚乙二醇400(PEG400),聚乙二醇600(PEG600);
助悬剂选自:三油酸甘油酯或单一酯酸甘油酯或其中一种或多种的混合物
比重调节剂如:滑石粉、硫酸钠、氯化钠、硬脂酸镁等、碳酸钙等;
防腐剂如:苯甲酸钠、尼泊金甲酯、尼泊金乙酯、尼泊金丙酯、尼泊金丁酯等;
抗氧化剂如:维生素C、维生素E、β-胡萝卜素等;
矫味剂如:薄荷油、甘油、各类香精等;
本发明的方法解决了使用1,1,1,2-四氟乙烷或1,1,1,2,3,3,3-七氟丙烷或其混合物为推进剂的药用气雾剂难于实施两步法罐装制备的缺陷,及成品罐内压力高的问题,方法简便易行,宜于规模型工业化生产。
具体实施方式
实施例1
组分: 重量:(%)
硫酸沙丁胺醇 0.085
油酸 0.009
无水硫酸钠 0.010
五氟丙烷 27.000
HFC-134a 72.896
实施例2
组分: 重量:(%)
硫酸沙丁胺醇 0.070
卵磷脂 0.006
氯化钠 0.012
五氟丙烷 25.000
HFC-134a 74.912
实施例3
组分: 重量:(%)
丙酸倍氯米松 0.060
司盘-80 0.007
滑石粉 0.008
苯甲酸钠 0.100
五氟丙烷 23.000
HFC-134a 49.800
HFC-227 27.025
实施例4
组分: 重量:(%)
异丙托溴铵 0.055
PEG400 0.008
硫酸镁 0.008
五氟丙烷 10.000
HFC-227 22.000
HFC-134a 67.929
实施例5
组分: 重量:(%)
布地奈德 0.100
吐温-20 0.007
无水硫酸钠 0.005
尼泊金乙酯 0.050
五氟丙烷 28.000
四氟乙烷(HFC-134A) 71.888
实施例6
组分: 重量:(%)
利多卡因 0.077
PEG400(聚乙二醇400) 0.006
维生素E 1.005
五氟丙烷 22.000
HFC-134a 76.912
实施例7
组分: 重量:(%)
硫酸沙丁胺醇 0.201
司盘-80 0.020
油酸 0.005
滑石粉 0.008
五氟丙烷 23.000
HFC-134a 76.766
实施例8
组分: 重量:(%)
硫酸左旋沙丁胺醇 0.085
油酸 0.007
薄荷油 0.010
无水乙醇 15.000
五氟丙烷 15.000
四氟乙烷(HFC-134A) 69.898
实施例9
组分: 重量:(%)
硫酸左旋沙丁胺醇 0.085
PEG400 0.006
三油酸甘油酯 3.000
无水乙醇 10.000
五氟丙烷 15.000
四氟乙烷(HFC-134A) 71.909
实施例10
组分: 重量:(%)
异丙托溴铵 0.095
司盘85 0.070
无水乙醇 9.000
五氟丙烷 14.000
四氟乙烷(HFC-134A) 76.835
实施例11
组分: 重量:(%)
沙美特罗 0.085
Tween 20(吐温20) 0.070
丙二醇 12.000
五氟丙烷 20.000
四氟乙烷(HFC-134A) 67.845
实施例12
组分: 重量:(%)
色甘酸钠 0.085
Myij-45(卖泽45) 0.009
丙二醇 15.000
五氟丙烷 10.000
HFC-134a 74.906
实施例13
组分: 重量:(%)
福莫特罗 0.100
PEG400 0.007
丙二醇 16.000
五氟丙烷 9.000
七氟丙烷(HFC-227A) 74.893
实施例14
组分: 重量:(%)
硫酸左旋沙丁胺醇 0.120
Tween-40 0.008
甘油 3.000
丙二醇 11.000
五氟丙烷 10.000
七氟丙烷(HFC-227A) 75.872
实施例15:
组分: 重量:(%)
硫酸左旋沙丁胺醇 0.100
PEG400 0.006
甘油 6.000
五氟丙烷 18.000
四氟乙烷(HFC-134A) 75.894
实施例16:
组分: 重量:(%)
硫酸左旋沙丁胺醇 0.075
卵磷脂 0.008
甘油 3.000
二甲醚 15.000
五氟丙烷 12.000
四氟乙烷(HFC-134A) 69.917
以上实施例按照上述制备方法制成成品。
Claims (3)
1.一种含生物活性成份的气雾剂制备方法,其特征在于该方法包括下列步骤:
①本发明气雾剂的活性成份与药用辅料按下列重量百分比组成:
活性成份 0.01%—1%
分散剂 五氟丙烷 5-28%
推进剂 1,1,1,2-四氟乙烷或1,1,1,2,3,3,3-七氟丙烷50-90%
稳定剂 0-16%
表面活性剂 0.001-0.5%
助悬剂 0-5%
比重调节剂 0-0.5%
矫味剂 0-0.5%
抗氧剂 0-1.5%
防腐剂 0-0.5%
②将固体原料经真空干燥或温度小于80℃的条件下加热干燥数小时,置于干燥器皿内冷却至室温备用;
③使用经干燥至恒重的无水硫酸钠,重量大于液体原料重量的20%,加入液体原料中脱水不少于24小时;
④将固体原料采用气流粉碎法粉碎,并使用粒度分析仪检查粉碎后的固体原料粒度小于10μm,大多数小于5μm,满足粒度要求合格的原辅料置于干燥器皿内密封保存备用;
⑤将处方量的活性成份、稳定剂、表面活性剂、助悬剂、比重调节剂、矫味剂、抗氧剂、防腐剂及分散剂共同置于密封的配制罐内,高速匀质后,检验中间体的质量及含量,按所设计的处方,将合格的中间体灌入耐压容器中,加盖阀门并密封,充入处方量的推进剂即可。
2.按权利要求1所述的一种含生物活性成份的气雾剂制备方法,其特征在于其中所述的生物活性成份选自抗变态反应药、支气管扩张药、支气管收缩药、肺部的肺表面活性剂、止痛剂、抗生素、白三烯抑制剂或拮抗剂、抗胆碱药、肥大细胞抑制剂、抗组胺药、抗肿瘤药、麻醉剂、抗结核药、显影剂、心血管药、酶、甾族化合物、基因物质或蛋白质的一种或任意二种的组合物。
3.按权利要求1所述的一种含生物活性成份的气雾剂制备方法,其特征在于其中所述的药用辅料为表面活性剂,稳定剂,助悬剂,比重调节剂、防腐剂、矫味剂和抗氧剂,其中
表面活性剂选自:
脱水山梨醇脂肪酸酯类:司盘20、司盘60、司盘65、司盘80或司盘85;
聚氧乙烯脱水山梨醇脂肪酸酯类:吐温20、吐温40、吐温60、吐温65、吐温80或吐温85;
聚氧乙烯脂肪酸酯类:卖泽45、卖泽52、卖泽53或卖泽59;
聚氧乙烯月桂酸酯类:聚氧乙烯(4)月桂酸酯、聚氧乙烯(8)月桂酸酯、聚氧乙烯(12)月桂酸酯、聚氧乙烯(24)月桂酸酯、聚氧乙烯(40)月桂酸酯或聚氧乙烯(100)月桂酸酯;
磷脂类:大豆磷脂或卵磷脂;
油酸或甘露醇;
稳定剂选自:乙醇、丙二醇、甘油、乙酸乙酯、聚乙二醇或二甲醚其中一种或多种的混合物;
聚乙二醇类:聚乙二醇200,聚乙二醇400或聚乙二醇600;
助悬剂选自:三油酸甘油酯或单一酯酸甘油酯其中一种或多种的混合物;
比重调节剂:滑石粉、硫酸钠、氯化钠、硬脂酸镁或碳酸钙;
防腐剂:苯甲酸钠、尼泊金甲酯、尼泊金乙酯、尼泊金丙酯或尼泊金丁酯;
抗氧化剂:维生素C、维生素E或β-胡萝卜素;
矫味剂:薄荷油、甘油或各类香精。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410084323XA CN100493608C (zh) | 2004-11-18 | 2004-11-18 | 含生物活性成份的气雾剂制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410084323XA CN100493608C (zh) | 2004-11-18 | 2004-11-18 | 含生物活性成份的气雾剂制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1778390A CN1778390A (zh) | 2006-05-31 |
CN100493608C true CN100493608C (zh) | 2009-06-03 |
Family
ID=36768926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200410084323XA Expired - Lifetime CN100493608C (zh) | 2004-11-18 | 2004-11-18 | 含生物活性成份的气雾剂制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100493608C (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100446770C (zh) * | 2007-01-10 | 2008-12-31 | 上海现代药物制剂工程研究中心有限公司 | 丙酸培氯米松水雾剂 |
CN100551988C (zh) * | 2007-02-27 | 2009-10-21 | 江苏阳生生物工程有限公司 | 不含氟里昂的气雾剂安全、高效复合抛射体系 |
CN103520106A (zh) * | 2012-07-02 | 2014-01-22 | 江苏山信药业有限公司 | 一种硫酸沙丁胺醇吸入气雾剂及其制备方法 |
CN105902494A (zh) * | 2016-06-07 | 2016-08-31 | 东莞市麦亘生物科技有限公司 | 一种新型气冷喷雾剂及其使用方法 |
CN107281524A (zh) * | 2017-05-18 | 2017-10-24 | 佛山市顺德区香江精细化工实业有限公司 | 一种干基清新剂及其制备方法 |
CN112110784B (zh) * | 2020-09-02 | 2022-03-15 | 天津科技大学 | 一种新型高含水量造雾剂 |
CN113025277B (zh) * | 2021-02-03 | 2022-07-12 | 天津科技大学 | 一种高效安全环保水性造雾剂 |
-
2004
- 2004-11-18 CN CNB200410084323XA patent/CN100493608C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1778390A (zh) | 2006-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5392880B2 (ja) | 加圧式定量吸入器のための安定な製薬学的溶液製剤 | |
US5776432A (en) | Beclomethasone solution aerosol formulations | |
AU658854B2 (en) | Aerosol formulation comprising beclomethasone 17,21 dipropionate | |
US5874063A (en) | Pharmaceutical formulation | |
CN1052401C (zh) | 药剂 | |
US20130068218A1 (en) | Process for producing metered dose inhaler formulations | |
RO121172B1 (ro) | Compoziţie farmaceutică de aerosol şi utilizarea acesteia | |
WO1998005302A1 (en) | Aerosol formulations | |
CN100493608C (zh) | 含生物活性成份的气雾剂制备方法 | |
EP1870090A2 (en) | Novel stable formulation of suspended aerosols and production method thereof | |
CN109464429B (zh) | 一种吸入压力定量气雾剂药物组合物及其制备方法 | |
CN101652123A (zh) | 稳定的药物气雾剂 | |
MXPA05002060A (es) | Composiciones farmaceuticas. | |
MXPA04009337A (es) | Formulaciones en suspension con hfa que contienen un anticolinergico. | |
MXPA04009338A (es) | Formulaciones de un anhidrato en suspension con hfa. | |
CN102362859A (zh) | 以氢氟烷烃为抛射剂的布地奈德气雾剂制剂 | |
US20070286815A1 (en) | Medicinal Aerosol Formulations and Methods of Synthesizing Ingredients Therefor | |
CN104208690A (zh) | 环索奈德、肾上腺素β2-受体激动剂分别包装并在一个吸入装置同时使用的药物组合物 | |
CN104208688A (zh) | 糠酸莫米松、肾上腺素β2-受体激动剂分别包装并在一个吸入装置同时使用的药物组合物 | |
CN104208687A (zh) | 不同活性成分分别包装并在一个吸入装置同时使用的干粉吸入药物组合物 | |
CN100457087C (zh) | 用于加压计量吸入器的稳定的药用溶液制剂 | |
CN1353980A (zh) | 速效平喘气雾剂及其制备方法 | |
CN104208686A (zh) | 氟替卡松、肾上腺素β2-受体激动剂分别包装并在一个吸入装置同时使用的药物组合物 | |
EP1785156B1 (en) | Metered dose inhaler containing an aerosol suspension formulation | |
JP5409594B2 (ja) | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: 271000 peitianmen street, high tech Industrial Development Zone, Tai'an City, Shandong Province Patentee after: JEWIM PHARMACEUTICAL (SHANDONG) CO.,LTD. Address before: 271000 middle section of Pioneer Street, hi tech Development Zone, Shandong, Tai'an Patentee before: JEWIM PHARMACEUTICAL (SHANDONG) CO.,LTD. |
|
CP02 | Change in the address of a patent holder |